Search

Your search keyword '"Schistosomiasis immunology"' showing total 2,044 results

Search Constraints

Start Over You searched for: Descriptor "Schistosomiasis immunology" Remove constraint Descriptor: "Schistosomiasis immunology"
2,044 results on '"Schistosomiasis immunology"'

Search Results

1. Schistosomiasis Chemotherapy, Chemoprevention, and Vaccines: History, Progress, and Priorities.

2. Schistosome and malaria exposure and urban-rural differences in vaccine responses in Uganda: a causal mediation analysis using data from three linked randomised controlled trials.

3. Activation of platelets and the complement system in mice with Schistosoma -induced pulmonary hypertension.

4. Deep humoral profiling coupled to interpretable machine learning unveils diagnostic markers and pathophysiology of schistosomiasis.

5. Intrapulmonary T Cells Are Sufficient for Schistosoma -Induced Pulmonary Hypertension.

6. Editorial: Conference research topic: 16th international symposium on schistosomiasis NEW ('th') presented in superscript.

7. Early symptom-associated inflammatory responses shift to type 2 responses in controlled human schistosome infection.

8. Functional autoantibodies against G protein-coupled receptors in hepatic and pulmonary hypertensions in human schistosomiasis.

9. Interstitial macrophage phenotypes in Schistosoma -induced pulmonary hypertension.

10. Schistosoma antigens: A future clinical magic bullet for autoimmune diseases?

11. Schistosoma japonicum EKLF/KLF1 is a potential immune target to tackle schistosomiasis.

12. CD18 controls the development and activation of monocyte-to-macrophage axis during chronic schistosomiasis.

13. Vaccines for Human Schistosomiasis: Recent Progress, New Developments and Future Prospects.

14. cGAS exacerbates Schistosoma japonicum infection in a STING-type I IFN-dependent and independent manner.

15. Schistosome immunomodulators.

16. Impact of Allium sativum ethanol extract on immuno-regulatory T cells and anti-inflammatory cytokine profile in murine schistosomiasis.

17. What is the impact of acquired immunity on the transmission of schistosomiasis and the efficacy of current and planned mass drug administration programmes?

18. Fetomaternal immune cross talk modifies T-cell priming through sustained changes to DC function.

19. Immunological and Biochemical Interplay between Cytokines, Oxidative Stress and Schistosomiasis.

20. Understanding the Pathophysiology of Exosomes in Schistosomiasis: A New Direction for Disease Control and Prevention.

21. Schistosomes in the Lung: Immunobiology and Opportunity.

22. Innovations and Advances in Schistosome Stem Cell Research.

23. Immunological Considerations for Schistosoma Vaccine Development: Transitioning to Endemic Settings.

24. Schistosome and intestinal helminth modulation of macrophage immunometabolism.

25. Molecular Context of ADP-ribosylation in Schistosomes for Drug Discovery and Vaccine Development.

26. Unveiling the Potential of Purinergic Signaling in Schistosomiasis Treatment.

27. Arachidonic Acid Is a Safe and Efficacious Schistosomicide, and an Endoschistosomicide in Natural and Experimental Infections, and Cysteine Peptidase Vaccinated Hosts.

28. Fine-scale heterogeneity in Schistosoma mansoni force of infection measured through antibody response.

29. The Potential Role of Schistosome-Associated Factors as Therapeutic Modulators of the Immune System.

30. IL-17A-producing γδ T cells promote liver pathology in acute murine schistosomiasis.

31. Behind Enemy Lines: Immunomodulatory Armamentarium of the Schistosome Parasite.

32. Genetic algorithms identify individuals with high risk of severe liver disease caused by schistosomes.

33. Whey milk proteomics from Schistosoma mansoni-infected mice reveals proteins involved in immunomodulation of the offspring.

34. Upregulation of KSRP by miR-27b attenuates schistosomiasis-induced hepatic fibrosis by targeting TGF-β1.

35. Concomitant Immunity and Worm Senescence May Drive Schistosomiasis Epidemiological Patterns: An Eco-Evolutionary Perspective.

36. T Lymphocyte-Mediated Liver Immunopathology of Schistosomiasis.

37. An ELISA based on soluble egg antigens for the serodiagnosis of animal schistosomiasis turkestanica.

38. An Efficient Schistosoma japonicum Bivalent Membrane Protein Antigen DNA Vaccine Against Schistosomiasis in Mice.

39. Th2 CD4 + T Cells Are Necessary and Sufficient for Schistosoma-Pulmonary Hypertension.

40. Molecular characterization and functional analysis of the Schistosoma mekongi Ca 2+ -dependent cysteine protease (calpain).

41. Recruitment of hepatic macrophages from monocytes is independent of IL-4Rα but is associated with ablation of resident macrophages in schistosomiasis.

42. The Advances in Molecular and New Point-of-Care (POC) Diagnosis of Schistosomiasis Pre- and Post-praziquantel Use: In the Pursuit of More Reliable Approaches for Low Endemic and Non-endemic Areas.

43. Molecular characterisation of immunological memory following homologous or heterologous challenges in the schistosomiasis vector snail, Biomphalaria glabrata.

44. Batf2 differentially regulates tissue immunopathology in Type 1 and Type 2 diseases.

45. The C-type Lectin Receptor-Driven, Th17 Cell-Mediated Severe Pathology in Schistosomiasis: Not All Immune Responses to Helminth Parasites Are Th2 Dominated.

46. The Role of Type 2 Inflammation in Schistosoma -Induced Pulmonary Hypertension.

47. Collaborative RNAS + research: Priorities and outcomes.

48. Population level changes in schistosome-specific antibody levels following chemotherapy.

49. ABO blood group antigens may be associated with increased susceptibility to schistosomiasis: a systematic review and meta-analysis.

50. Is POC-CCA a truly reliable test for schistosomiasis diagnosis in low endemic areas? The trace results controversy.

Catalog

Books, media, physical & digital resources